<http://schema.org/description>
"Vemurafenib has been approved since February 2012 for the treatment of certain groups of adults with advanced melanoma. The drug offers major advantages in terms of survival, but also causes major side effects. Overall, there is an indication of a considerable added benefit. This is the conclusion of a dossier assessment by the IQWiG, Cologne, which was published in June 2012 and for which an English-language extract is now available."^^<http://www.w3.org/2001/XMLSchema#string>
<http://medicalxpress.com/news/2013-01-indication-considerable-added-benefit-vemurafenib.html>